Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05614466 | The SIMPLY-B Study | unknown | N/A | 100 | Nadine BarnesOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT04718909 | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC(REGSIN) | unknown | Phase 2 | 166 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05596370 | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer | unknown | — | 150 | Seoul National University HospitalOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05604716 | Cross-sectional Follow-up on Digestive and Social Functions of SPN | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05594914 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 47 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05575622 | Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma | unknown | — | 200 | Zhongnan HospitalOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05257694 | Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning | unknown | — | 1 | Ping LiangOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05573282 | Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma | unknown | — | 50 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05582278 | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | unknown | Phase 2 | 60 | Wen LiOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05580224 | Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma | unknown | N/A | 87 | Seoul National University HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05580835 | PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma | unknown | N/A | 100 | University of Sao PauloOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05580887 | Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients | unknown | — | 35 | Moscow Clinical Scientific CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05449873 | No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes | unknown | N/A | 73 | Seoul National University HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05571956 | Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples | unknown | N/A | 50 | Ajou University School of MedicineOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT05572528 | Lenvatinib Therapy in HCC Patients After LDLT | unknown | — | 30 | Kaoshiung Chang Gung Memorial HospitalOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05561699 | Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer(SPEED) | unknown | N/A | 66 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05552651 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tao JiangOTHER | 0 | Sep 23, 2022 | clinicaltrials |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05545124 | Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence | unknown | Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04967482 | DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC | unknown | N/A | 216 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05522894 | AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 31, 2022 | clinicaltrials |
| NCT05519410 | Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT02526043 | Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma | unknown | N/A | 180 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04856761 | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | unknown | — | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05493332 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | unknown | Phase 2 | 93 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT04699994 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | unknown | Phase 2 | 60 | Keio UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03744624 | Application of 3D Printing in Laparoscopic Surgery of Liver Tumors | unknown | N/A | 85 | Jagiellonian UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT05170256 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients(HERES) | unknown | Phase 2 | 24 | Morten Mau-SørensenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05059821 | Personalized Cancer Vaccine in Egyptian Cancer Patients(PROVE) | unknown | Phase 1 | 10 | zeinab ahmed yousif hasan ashourOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05488587 | Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients | unknown | — | 100 | Sohag UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05493878 | ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer | unknown | — | 128 | Assiut UniversityOTHER | 0 | Aug 9, 2022 | clinicaltrials |
| NCT05491889 | Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization | unknown | — | 30 | Assiut UniversityOTHER | 0 | Aug 8, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05490147 | Effect of Low Tidal Ventilation on Intraoperative Bleeding in Laparoscopic Major Hepatectomy | unknown | N/A | 58 | Seoul National University HospitalOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03838796 | Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | unknown | N/A | 297 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05442138 | A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients | unknown | — | 54 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 29, 2022 | clinicaltrials |
| NCT05476380 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Nov 14, 2022source: clinicaltrials